Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;20(6):e190724232038.
doi: 10.2174/011573403X302934240715113647.

Volatilome is Inflammasome- and Lipidome-dependent in Ischemic Heart Disease

Affiliations
Review

Volatilome is Inflammasome- and Lipidome-dependent in Ischemic Heart Disease

Basheer Abdullah Marzoog. Curr Cardiol Rev. 2024.

Abstract

Ischemic heart disease (IHD) is a pathology of global interest because it is widespread and has high morbidity and mortality. IHD pathophysiology involves local and systemic changes, including lipidomic, proteomic, and inflammasome changes in serum plasma. The modulation in these metabolites is viable in the pre-IHD, during the IHD period, and after management of IHD in all forms, including lifestyle changes and pharmacological and surgical interventions. Therefore, these biochemical markers (metabolite changes; lipidome, inflammasome, proteome) can be used for early prevention, treatment strategy, assessment of the patient's response to the treatment, diagnosis, and determination of prognosis. Lipidomic changes are associated with the severity of inflammation and disorder in the lipidome component, and correlation is related to disturbance of inflammasome components. Main inflammasome biomarkers that are associated with coronary artery disease progression include IL-1β, Nucleotide-binding oligomerization domain- like receptor family pyrin domain containing 3 (NLRP3), and caspase-1. Meanwhile, the main lipidome biomarkers related to coronary artery disease development involve plasmalogen lipids, lysophosphatidylethanolamine (LPE), and phosphatidylethanolamine (PE). The hypothesis of this paper is that the changes in the volatile organic compounds associated with inflammasome and lipidome changes in patients with coronary artery disease are various and depend on the severity and risk factor for death from cardiovascular disease in the time span of 10 years. In this paper, we explore the potential origin and pathway in which the lipidome and or inflammasome molecules could be excreted in the exhaled air in the form of volatile organic compounds (VOCs).

Keywords: Lipidome; VOCs; coronary artery disease.; inflammasome; ischemic heart disease; metabolome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1)
Fig. (1)
Role of the TRPM2 and CD36 in the atherogenesis process. Inhibiting CD36 reduces TRPM2 signaling activity and furthers atherosclerosis formation. The opposite occurs when inhibiting the TRPM2 downregulation in the activity of the CD36 experience. Abbreviations: oxLDL; oxidative low-density lipoprotein.
Fig. (2)
Fig. (2)
The suggested algorithm includes adding exhaled breath analysis, lipidome, and inflammasome analysis to the classical physical stress test to increase the accuracy of diagnosis. Additionally, using the results can be a novel non-classical risk factor for the prediction of cardiovascular disease. The machine learning model can be added to interpret the results of the lipidome, inflammasome, and volatilome for rapid and worldwide applied method techniques such as programs for global use.

Similar articles

Cited by

References

    1. Tsao C.W., Aday A.W., Almarzooq Z.I., et al. Heart disease and stroke statistics—2023 update: A report from the American heart association. Circulation. 2023;147(8):e93–e621. doi: 10.1161/CIR.0000000000001123. - DOI - PubMed
    1. Salonen I., Huttunen K., Hirvonen M.R., et al. Exhaled nitric oxide and atherosclerosis. Eur. J. Clin. Invest. 2012;42(8):873–880. doi: 10.1111/j.1365-2362.2012.02662.x. - DOI - PubMed
    1. Nurmohamed N.S., Kraaijenhof J.M., Mayr M., et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur. Heart J. 2023;44(18):1594–1607. doi: 10.1093/eurheartj/ehad161. - DOI - PMC - PubMed
    1. Močnik M., Marčun Varda N. Lipid biomarkers and atherosclerosis—old and new in cardiovascular risk in childhood. Int. J. Mol. Sci. 2023;24(3):2237. doi: 10.3390/ijms24032237. - DOI - PMC - PubMed
    1. Zhu D., Vernon S.T., D’Agostino Z., et al. Lipidomics profiling and risk of coronary artery disease in the BioHEART-CT discovery cohort. Biomolecules. 2023;13(6):917. doi: 10.3390/biom13060917. - DOI - PMC - PubMed

LinkOut - more resources